166 related articles for article (PubMed ID: 34418218)
1. Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with novel NPHP3-JAK2 fusion.
Chen X; Yuan L; Zhou J; Wang F; Zhang Y; Ma X; Cao P; Fang J; Chen J; Zhou X; Wu Q; Liu M; Liu H
Genes Chromosomes Cancer; 2022 Jan; 61(1):55-58. PubMed ID: 34418218
[No Abstract] [Full Text] [Related]
2. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with
Ding YY; Stern JW; Jubelirer TF; Wertheim GB; Lin F; Chang F; Gu Z; Mullighan CG; Li Y; Harvey RC; Chen IM; Willman CL; Hunger SP; Li MM; Tasian SK
Haematologica; 2018 Sep; 103(9):e427-e431. PubMed ID: 29773603
[No Abstract] [Full Text] [Related]
3. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
4. Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome-like Relapsed/Refractory acute lymphoblastic leukemia.
Bayram N; Yaman Y; Özdilli K; Telhan L; Nepesov S; Bilgen H; Elli M; Behar SS; Anak S
Pediatr Transplant; 2021 Jun; 25(4):e14024. PubMed ID: 33860589
[TBL] [Abstract][Full Text] [Related]
5. Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.
Schewe DM; Lenk L; Vogiatzi F; Winterberg D; Rademacher AV; Buchmann S; Henry D; Bergmann AK; Cario G; Cox MC
Blood Adv; 2019 Nov; 3(22):3499-3502. PubMed ID: 31725893
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of the first adult case of ZMIZ1::ABL1-positive B cell lymphoblastic leukemia with dasatinib, chimeric antigen receptor T-cell therapy, and allogeneic hematopoietic stem cell transplantation.
Chen X; Yuan L; Ma X; Cao P; Wang F; Zhang Y; Chen J; Zhang X; Zhao Y; Liu H
Cancer Genet; 2024 Jun; 284-285():16-19. PubMed ID: 38503133
[No Abstract] [Full Text] [Related]
7. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Zeeh FC; Meyer SC
Hamostaseologie; 2021 Jun; 41(3):197-205. PubMed ID: 34192778
[TBL] [Abstract][Full Text] [Related]
8. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Yang X; Dai H; Kang L; Qu C; Li Z; Yin J; Qiu H; Fu C; Han Y; Jin Z; Ma X; Zhu X; Yu L; Wu D; Tang X
Hematol Oncol; 2019 Dec; 37(5):655-658. PubMed ID: 31656047
[No Abstract] [Full Text] [Related]
9. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function.
Wei S; Gu R; Xu Y; Liu X; Xing Y; Gong X; Zhou C; Liu B; Zhang G; Liu K; Wei H; Mi Y; Wang M; Wang Y; Wang J
Immunotherapy; 2020 Oct; 12(14):1047-1052. PubMed ID: 32777959
[No Abstract] [Full Text] [Related]
11. CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yao Z; Gu B; Zhang Y; Qi J; Chen J; Xu Y; Chen F; Ma X; Miao M; Xue S; Qiu H; Tang X; Han Y; Chen S; Sun A; Yu L; Wu D; Wang Y
Bone Marrow Transplant; 2023 Jan; 58(1):103-105. PubMed ID: 36253466
[No Abstract] [Full Text] [Related]
12. Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia: A case report.
Yang M; Liu B; Wang Y; Liu Y; Gong X; Gong B; Xu Y; Mi Y; Wang M; Wang J
Medicine (Baltimore); 2020 May; 99(18):e18639. PubMed ID: 32358340
[TBL] [Abstract][Full Text] [Related]
13. Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.
Mayfield JR; Czuchlewski DR; Gale JM; Matlawska-Wasowska K; Vasef MA; Nickl C; Pickett G; Ness SA; Winter SS
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27860260
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
[TBL] [Abstract][Full Text] [Related]
15. Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.
Chen X; Wang F; Zhang Y; Ma X; Liu M; Cao P; Zhou L; Wang L; Zhang X; Wang T; Liu H
Mol Genet Genomic Med; 2020 Mar; 8(3):e1110. PubMed ID: 31885183
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and
Lee WY; Pfau RB; Choi SM; Yang J; Xiao H; Putnam EM; Ryan RJ; Bixby DL; Shao L
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238402
[TBL] [Abstract][Full Text] [Related]
17. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.
Zi FM; Ye LL; Zheng JF; Cheng J; Wang QM
Medicine (Baltimore); 2021 May; 100(19):e25786. PubMed ID: 34106613
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.
Wang T; Wan X; Yang F; Shi W; Liu R; Ding L; Tang Y; Luo C; Yang X; Ma Y; Wang X; Liang H; Li B; Lu J; Chen J
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):386-392. PubMed ID: 33640284
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
Wouters Y; Nevejan L; Louwagie A; Devos H; Dewaele B; Selleslag D; Michaux L
Br J Haematol; 2021 Feb; 192(4):e112-e115. PubMed ID: 33502001
[No Abstract] [Full Text] [Related]
20. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]